Delving into the Latest Updates on Green Cross China Biological Products Co., Ltd. with Synapse

Overview

Tags

Other Diseases

Congenital Disorders

Nervous System Diseases

Non-recombinant coagulation factor

Enzyme

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Hemic and Lymphatic Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Non-recombinant coagulation factor	1
Enzyme	1

Top 5 Target	Count

GAG(Glycosaminoglycan)	1
Fibrinogen	1

主要目的：评估艾度硫酸酯酶β注射液治疗中国黏多糖贮积症II型（MPS II）儿童患者的安全性次要目的： 1、评估中国MPSⅡ患者接受艾度硫酸酯酶β注射液治疗后患者尿糖胺聚糖（uGAG）较基线的变化 2、评估中国MPSⅡ患者接受艾度硫酸酯酶β注射液治疗后患者肝脏和脾脏体积较基线的变化百分比

[Translation]

Primary Objective: To evaluate the safety of idolisulfate beta injection in Chinese pediatric patients with mucopolysaccharidosis type II (MPS II). Secondary Objectives: 1. To assess the change in urinary glycosaminoglycans (uGAG) levels from baseline in Chinese MPS II patients treated with idolisulfate beta injection. 2. To assess the percentage change in liver and spleen volume from baseline in Chinese MPS II patients treated with idolisulfate beta injection.

Start Date27 Aug 2026

Sponsor / Collaborator

Nuoai Pharmaceutical (Shanghai) Co., Ltd.

[+1]

CTR20241641

/ CompletedPhase 4

评价人纤维蛋白原在先天性纤维蛋白原减少或缺乏症患者中的有效性和安全性的上市后临床研究

[Translation] Post-marketing clinical study to evaluate the efficacy and safety of human fibrinogen in patients with congenital fibrinogen deficiency or deficiency

1)通过单次给药的简易PK研究，探索本品的部分关键药代动力学(PK)特征，为本品用量计算提供依据; 2)评价本品在上市后治疗先天性纤维蛋白原减少或缺乏症患者的有效性和安全性。

[Translation]

1) Through a simple PK study of a single dose, explore some key pharmacokinetic (PK) characteristics of this product to provide a basis for the dosage calculation of this product; 2) Evaluate the efficacy and safety of this product in the treatment of patients with congenital fibrinogen deficiency or deficiency after marketing.

Start Date09 Aug 2024

Sponsor / Collaborator

Green Cross China Biological Products Co., Ltd.

CTR20180860

/ Not yet recruitingPhase 3

评价静注人免疫球蛋白(pH4)治疗原发免疫性血小板减少症有效性和安全性的临床研究

[Translation] Clinical study to evaluate the efficacy and safety of intravenous human immunoglobulin (pH4) in the treatment of primary immune thrombocytopenia

以原生产工艺静注人免疫球蛋白(pH4)对照，评价静注人免疫球蛋白(pH4)治疗原发免疫性血小板减少症的有效性和安全性。

[Translation]

To evaluate the efficacy and safety of intravenous human immunoglobulin (pH4) in the treatment of primary immune thrombocytopenia, using the original production process of intravenous human immunoglobulin (pH4) as a control.

Start Date-

Sponsor / Collaborator

Green Cross China Biological Products Co., Ltd.

100 Clinical Results associated with Green Cross China Biological Products Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Green Cross China Biological Products Co., Ltd.

Login to view more data

100 Deals associated with Green Cross China Biological Products Co., Ltd.

Login to view more data

100 Translational Medicine associated with Green Cross China Biological Products Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

2

Login to view more data